Allogene Therapeutics Inc’s recent filing unveils that its President and CEO Chang David D unloaded Company’s shares for reported $91469.0 on Mar 14 ’25. In the deal valued at $1.96 per share,46,668 shares were sold. As a result of this transaction, Chang David D now holds 5,276,569 shares worth roughly $8.92 million.
Then, Beneski Benjamin Machinas sold 5,488 shares, generating $10,839 in total proceeds. Upon selling the shares at $1.98, the SVP, Chief Technical Officer now owns 218,507 shares.
Before that, Beneski Benjamin Machinas bought 5,488 shares. Allogene Therapeutics Inc shares valued at $10,839 were divested by the Officer at a price of $1.97 per share.
Citizens JMP upgraded its Allogene Therapeutics Inc [ALLO] rating to a Mkt outperform from a a Mkt perform in a research note published recently. Piper Sandler began covering ALLO with “an Overweight” recommendation on May 31, 2024. JMP Securities revised its rating on January 05, 2024. It rated ALLO as “a Mkt perform” which previously was an “a Mkt outperform”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -8.65% to $1.69. Over the last five days, the stock has lost -16.75%. Allogene Therapeutics Inc shares have fallen nearly -20.66% since the year began. Nevertheless, the stocks have fallen -62.40% over the past one year. While a 52-week high of $4.74 was reached on 02/19/25, a 52-week low of $1.32 was recorded on 02/12/25. SMA at 50 days reached $1.9309, while 200 days put it at $2.3912.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 1.6367, which if violated will result in even more drops to 1.5833. On the upside, there is a resistance level at 1.7967. A further resistance level may holdings at 1.9033. The Relative Strength Index (RSI) on the 14-day chart is 41.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1190, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 100.00%. Stochastics %K at 32.28% indicates the stock is a holding.
How much short interest is there in Allogene Therapeutics Inc?
A steep rise in short interest was recorded in Allogene Therapeutics Inc stocks on 2025-02-28, growing by 7.05 million shares to a total of 39.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 32.05 million shares. There was a rise of 18.03%, which implies that there is a positive sentiment for the stock.
